Celularity Inc

Celularity Inc. entered public markets through its 2021 business combination with GX Acquisition Corp. II, a blank-check company sponsored by GX Sponsor II LLC that completed its IPO in 2020 and traded under the ticker GXGX. The post-merger entity, a clinical-stage biotechnology company developing off-the-shelf cellular medicines derived from the human placenta, filed an 8-K with the SEC on February 26, 2024, disclosing a material corporate event in its ongoing public-company operations. Celularity's programs target oncology and infectious disease indications within the broader cell and gene therapy segment of the life sciences sector. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on this and every active SPAC.